About the Company
We do not have any company description for Solid Biosciences Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Solid Biosciences Inc.
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue ... - Nasdaq
Solid Biosciences Inc. (SLDB) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.17 per share a year ago.
Solid Biosciences Inc. Included in Nasdaq Biotechnology Index ...
Solid Biosciences Inc., a company specializing in precision genetic medicines for neuromuscular and cardiac diseases, announced its inclusion in the Nasdaq Biotechnology Index, effective December ...
Solid Biosciences Reports Third Quarter 2024 Financial Results and ...
CHARLESTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for ...
Solid Biosciences Reports Increased Assets Amid Ongoing Losses
Solid Biosciences ( ($SLDB) ) has released its Q2 earnings. Here is a breakdown of the information Solid Biosciences presented to its investors.
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to ...
27,100 Shares in Solid Biosciences Inc. (NASDAQ:SLDB) Acquired by ...
Solid Biosciences Inc. has a one year low of $2.41 and a one year high of $10.37. The business’s fifty day moving average is $5.14 and its 200 day moving average is $4.25.
Solid Biosciences Receives FDA Fast Track Designation for Duchenne ...
Solid Biosciences Contact: Leah Monteiro VP, Investor Relations and Communications 617-766-3430 lmonteiro@solidbio.com Source: Solid Biosciences Inc. 2023 GlobeNewswire, Inc.
Solid Biosciences says FDA lifts halt on gene therapy trial ... - Yahoo
(Reuters) - Solid Biosciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) has lifted the clinical halt placed on a trial of its experimental gene therapy for Duchenne muscular ...
Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and ...
Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results ...
Solid Biosciences Inc. (NASDAQ:SLDB) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ETCompany ParticipantsCaitlin Lowie - VP, Communications and ...
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Similar Companies
Loading the latest forecasts...